Similar Items: Would you, could you drive CARs to point-of-care manufacturing? Yes, you should!
- Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma: a multicenter propensity scorematched analysis
- Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report
- ChREBP drives β‐cell proliferation under metabolic stress but not in pregnancy‐induced β‐cell expansion
- Research Progress on Transitional Care for Hemophilia Patients from Pediatric to Adult Services: Focusing on Disease Severity and Care Continuity
- Optimizing Care in Patients with Paroxysmal Nocturnal Hemoglobinuria: Managing Suboptimal Response and Uncontrolled Disease
- Characterization of Inherited Bleeding Disorders in Egyptian Children in a Tertiary Care Center: A 10 Years Experience